PPT-Medications for Longevity: An Evidence Based Overview

Mark Shehata MD MBA Learning Objectives At the conclusion of this presentation participants should be able to 1 Describe basic theories of aging 2 Recognize the proposed mechanism of action of metformin acarbose and rapamycin in combating aging. presented by . Paul St. Laurent, MSN, RN, ACNP, CCRN. Acute Care Nurse Practitioner. Baylor Heart and Vascular Hospital. What Do We Already Know?. Aspirin reduces the risk of myocardial infarction. Antiplatelet therapy reduces stent thrombosis. . An overview of measures for perserving evidence in the EU. State of the law regarding the preservation of evidence in Europe. Towards a unification concerning measures for preserving evidence. Directive 2004/48/EC of the European parliament and of the Council of 29 April 2004 on the enforcement of intellectual property rights. Leonid A. Gavrilov. Natalia S. Gavrilova. . Center on Aging . NORC and The University of Chicago . Chicago, USA. Approach . To study “success stories” in long-term avoidance of fatal diseases (survival to 100 years) and factors correlated with this remarkable survival success. Leonid A. Gavrilov. Natalia S. Gavrilova. . Center on Aging . NORC and The University of Chicago . Chicago, USA. Approach . To study “success stories” in long-term avoidance of fatal diseases (survival to 100 years) and factors correlated with this remarkable survival success. and Related Disorders. January 11, 2017. Jean B. Mankowski, PhD. Carolina Institute for Developmental Disabilities . UNC School of Medicine. 1. Evidence Based Treatments . Comprehensive Treatment Models (CTM). Longevity 12. September 2016. Laura Hardy. A Balancing Act. Servicing demand at a price that works. Is reinsurer longevity capacity running out?. Global exposure currently supports local appetite . US mortality exposure $12trn Sum Assured**. Janna Hawthorne, . pharmd. , MA ed. primary care clinical pharmacist. baptist. health/practice plus. No conflicts of interest to disclose. Objectives:. Measure the burden of medications on patients 65 years of age and older, including presence of adverse drug reactions. EVIDENCE BASED DECISION-MAKING SUMMARY147When somebody on staff asks what we should do to 145What does the research say What is the evidence base What information can we gather to determine if it wil September 2020. Introduction. Schizophrenia…. Significant health, social, occupational, and economic burdens as a result of its early onset and its severe and often persistent symptoms. One of the top 20 causes of disability worldwide. ) is . about systematically . reviewing, appraising, and using clinical research findings to aid the delivery of optimum clinical care to patients. . Patient . knowledge of . EBM . is important because it enables them to make more informed decisions about disease management and treatment. . Advisory Committee on Data for Evidence Building. October 23, 2020. 1. What is the Evidence Act? . Background: The Commission on Evidence-Based Policymaking. Established by 2016 bipartisan . legislation . Brian Fuehrlein MD PhD. YALE UNIVERSITY SCHOOOL OF MEDICINE. Disclosure. No conflicts of interest to disclose. Objectives. To introduce a basic overview of substance use disorders (SUD).. To provide evidence for medications for SUDs among individuals with co-occurring disorders (COD).. Overview. Principles of Good Medical Practice (GMP). I. Commonly used medications in ASD . II. Nutraceuticals and supplements in ASD. III. Research trends in psychopharmacology for ASD. IV. The role of parents and caregivers in medication management. Leah Cordova, MLIS. Assistant Professor | Research and Learning Services Librarian . Today’s . Discussion. Brief Overview of EBM. EBM Library Resources . Primary original research. Secondary pre-appraised .